Teva, after Lupin deal, holds another Austedo generic challenger to a 2033 launch

As Teva leans on tardive dyskinesia med Austedo for growth, the company can feel comfortable that it has a long runway clear from generics⁠—at least from two prominent challengers.

Teva has closed the books on its patent infringement lawsuit against Aurobindo over the Indian company's application to market a generic of Austedo.